Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 2, 2019--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the company is scheduled to present and subsequently participate in a Q&A session at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 9:30 a.m. PT (12:30 p.m. ET).
A live webcast of the presentation and Q&A session can be accessed under the “Events & Presentations” page within the Investors & Media section of the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations. A replay of the webcast will be available on the Magenta Therapeutics website for 90 days following the event.
About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.
This press release may contain forward-looking statements, including express or implied statements regarding Magenta’s future expectations, plans and prospects, including projections regarding future revenues and financing performance, our long-term growth, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates and advancement of our preclinical programs, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” might,” “plan,” “potential,” “project,” “should,” target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. Although Magenta’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Magenta’s programs and operations are described in additional detail in its registration statement on Form S-1, its Quarterly Report on Form 10-Q and its other filings made with the Securities and Exchange Commission from time to time. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005142/en/
CONTACT: Magenta Therapeutics:
Manisha Pai, Vice President, Communications & Investor Relations
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL GENERAL HEALTH
SOURCE: Magenta Therapeutics
Copyright Business Wire 2019.
PUB: 01/02/2019 08:30 AM/DISC: 01/02/2019 08:31 AM